iCUREX targets the difficulty of treating narrow, irregular wounds, where its injectable chitosan hydrogel is designed to fill the wound and maintain a moist healing environment, while its NasaPure products address at-home nasal care. Its first advanced medical device, Kitosla CX, received Japanese Class III approval on 2026-05-01 and launched in September 2026, and the Series A first close is intended to fund manufacturing capacity, quality management, market rollout and next-generation R&D.